Germano Geno J
Germano Geno J's purchase track record
How the stock did after each of Germano Geno J's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/25/2026 | DTIL | $16K | pending | pending | — |
| 3/9/2026 | ENTX | $26K | -9.8% | +126.3% | +12.9% |
| 2/10/2026 | ENTX | $30K | -13.8% | +106.9% | +11.3% |
| 12/16/2025 | DTIL | $14K | +43.8% | +30.9% | +10.5% |
| 3/25/2025 | DTIL | $17K | -10.2% | -4.1% | +15.2% |
| 12/30/2024 | DTIL | $16K | +12.0% | -1.4% | +5.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Entera Bio gets new coverage from Guggenheim and Cantor. Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.
Transaction History
| DTIL | ▲ Buy | Open Market | 2,609 | $16K | 9/25/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 25,014 | $0 | 8/7/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 21,000 | — | 5/20/2026 | View on chart |
| ENTX | ▲ Buy | Open Market | 20,000 | $26K | 3/9/2026 | View on chart |
| ENTX | ▲ Buy | Open Market | 20,000 | $30K | 2/10/2026 | View on chart |
| DTIL | ▲ Buy | Open Market | 3,000 | $14K | 12/16/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 9,826 | — | 5/27/2025 | View on chart |
| DTIL | ▲ Buy | Open Market | 3,250 | $17K | 3/25/2025 | View on chart |
| DTIL | ▲ Buy | Open Market | 3,605 | $16K | 12/30/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 4,202 | — | 5/4/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.